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1 
  
SUPERVISED WALKING IMPROVES AEROBIC CAPACITY, EXERCISE TOLERANCE AND 
FATIGUE IN WOMEN WITH PRIMARY SJÖGREN’S SYNDROME: A RANDOMIZED 
CONTROLLED TRIAL 
 
ABSTRACT 
Objective: The aim of this study was to evaluate the safety and effectiveness of a supervised walking 
program in women with primary Sjögren’s syndrome (pSS). 
Methods: Forty five sedentary women fulfilling the American European Consensus Criteria for pSS were 
randomized to a Training Group (TG, n= 23) or Control Group (CG, n= 22). Patients in the TG were 
submitted to supervised walking 3 times a week for 16 weeks. The patients of the CG were instructed to 
not perform any kind of regular physical exercise. Cardiorespiratory fitness, EULAR Sjögren’s Syndrome 
Disease Activity Index (ESSDAI), haematological tests and Medical Outcomes Study 36 (SF-36) were 
assessed at baseline and week 16. Patients were interviewed by EULAR Sjögren’s Syndrome Patient 
Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-
Fatigue) and Beck Depression Inventory (BDI) prior to intervention, after 8 and 16 weeks. Patient global 
assessment of response to therapy (PGART) was completed at the final assessment. An intent-to-treat 
analysis was performed. 
Results: The mean change after 16 weeks of maximum oxygen uptake (VO2max (ml/kg/min)), distance and 
FACIT-fatigue were higher in the TG than in the CG (p= 0.016, p= 0.043 and p= 0.030, respectively). 
Improved cardiorespiratory fitness was associated with improvements in fatigue scores and physical 
components of quality of life measured using SF-36. Furthermore, improved fatigue scores were 
associated with reduced depression and improvements in the physical and mental components of the 
quality of life measures. Overall, 95.4% of patients in the TG rated themselves as clinically improved 
versus 62% of the patients in the CG (p= 0.049). There was no flare in disease activity and no serious 
adverse events with exercise. 
Conclusions: This supervised walking program was demonstrated to be feasible and safe with 
improvements in the aerobic capacity, exercise tolerance, fatigue and patient perception of improvement 
in pSS patients. 
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INTRODUCTION 
There is emerging evidence that exercise training can improve physical capacity, muscle function and 
several clinical symptoms, such as fatigue, pain and depression, in many autoimmune rheumatic 
diseases(1). Furthermore, exercise training may have an anti-inflammatory effect based on studies in 
older adults(2,3) and in low-grade systemic inflammation chronic diseases, such as type 2 diabetes 
mellitus and congestive heart failure(4,5). Aerobic exercise has been investigated in rheumatoid arthritis 
(RA)(6), systemic lupus erythematous (SLE)(7–11), ankylosing spondylitis (AS)(12) and systemic 
sclerosis (SS). Primary Sjögren’s syndrome (pSS) is also a systemic autoimmune disease, but there is 
only one non-randomized controlled study on aerobic exercise with a small sample size, suggesting 
improvement in fatigue, aerobic capacity, depression and physical function(13). This disease is 
characterized by lymphocytic infiltration and progressive destruction of exocrine glands, leading to dry 
eyes and dry mouth(14). In addition, around 20-40% of patients present with severe systemic 
manifestations and most of them report pain and fatigue(15), decreasing their quality of life(16–19). 
There is also a high prevalence of depression(20) and sleep disorders(21). 
When compared to healthy controls, pSS patients have reduced levels of physical activity(22,23) and 
cardiorespiratory fitness(22,24). In Ng et al study, fatigue was a predictor of vigorous and moderate 
intensities of physical activity, whereas symptoms of depression and daytime sleepiness accounted for 
4.5% of the variance of total physical activity levels(23). In our preliminary cross-sectional study 20 pSS 
patients performed a maximum treadmill test and had their expired gas analysed by a computerized 
metabolic system. Lower levels of maximum oxygen uptake (VO2max, ml/kg/min) were associated with 
worse symptoms measured by ESSPRI, mainly fatigue and dryness(25). Strömbeck et al also found an 
association between aerobic capacity (VO2max, l/min), measured indirectly, and fatigue(24). Moreover, 
Wouters et al have shown that the combination of low physical activity and high activity avoidance was 
associated with more severe fatigue(26). In fact, patients often report that fatigue is their greatest problem 
and the most difficult to cope with(27), affecting up to 70% of the patients(28). However, its pathogenesis 
is unknown and, so far, there is no evidence of high quality of an effective treatment. These observations 
may imply that programmes designed to increase the levels of physical activity and cardiorespiratory 
fitness may ameliorate pSS symptoms, mostly fatigue.  
This paper reports the first randomized controlled trial to evaluate the safety and effectiveness of a 
supervised aerobic exercise program in women with pSS. 
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METHODS 
This is a randomized controlled trial with intention-to-treat analysis. Forty-five sedentary women 
fulfilling the American European Consensus Criteria for pSS(29) were recruited from the rheumatology 
outpatient clinic of an University hospital in the city of Vitória/Brazil, from 2012 to 2015, and 
randomized into Training Group (TG) and Control Group (CG). Patients were screened for entry into the 
study by just one investigator (rheumatologist) who was blind to forthcoming patients’ allocation. This 
trial was open to patients between 18 and 65 years old. Patients with symptomatic cardiac failure, body 
mass index>40, using beta-blocker therapy, presenting severe systemic manifestations limiting or 
hindering walking performance, or those who had performed regular physical activity in the 6 weeks 
before trial were excluded. 
To investigate the improvement in VO2max (ml/kg/min) and its association with improvement of clinical 
outcomes, this study was powered to achieve an improvement in VO2max of 3.8 ml/kg/min, given an 
estimated SD of 2.76 with a statistical significance at 1% and power of 95% leading to a recommended 
minimum of 19 patients per group. However, 45 patients were included and all of them were analysed. 
[(9,13)  Not clear to me what these limits refers to and I suspect they’re not used in the power calculation 
anyway?] 
The Centro de Ciências da Saúde Ethics Committee/UFES (number 084/11) approved the study according 
to the Declaration of Helsinki. Informed consent was obtained from all individual participants included in 
the study. 
 
Procedures 
Demographic and clinical assessments to evaluate disease activity were performed by a rheumatologist 
expert in Sjögren’s syndrome. A trained interviewer, blinded to treatment allocation throughout the trial, 
conducted the other questionnaires. The treadmill tests were performed by a cardiologist and assisted by a 
laboratory technician and a physiologist.  
At baseline, all patients had their demographic data collected, including age, body mass index (BMI), 
marital status, education level, working status and social class (Brazil Economic Classification Criteria-
CCEB)(30). Clinical assessments, such as complains of xerostomia and xerophthalmia, comorbidities, 
medications in use, sialodenitis (focus score>1 on labial salivary gland biopsy) and unstimulated salivary 
flow rate (5 minutes) were taken at the moment of the evaluation and/or confirmed in patient’s medical 
record. Haematological tests, including erythrocyte sedimentation rate (ESR), C reactive protein (CRP), 
creatine kinase (CK), IgG, IgA, IgM, C3, C4 anti-Ro and anti-La were performed at the hospital’s 
analytical laboratory and assessed at baseline and week 16. Physical fitness, disease activity and quality 
of life were also evaluated at baseline and week 16. Patients were interviewed to evaluate fatigue, 
depression and perception of pSS’s symptoms prior to intervention, after 8 and 16 weeks.  
Patients were allocated to groups by randomization drawing lots after the initial assessment: folded pieces 
of paper in which the group labels were written (either TG, or CG) were held in sealed envelopes. One of 
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the investigators, who remained unaware of screening and assessments of the patients, took the envelopes 
out of a container. Both groups received the usual pharmacological treatment.  The patients of the CG 
were instructed to not perform any kind of regular physical exercise for 16 weeks. The patients of the TG 
were submitted to a supervised walking in an outdoor track field (400m), 3 times a week for 16 weeks, by 
two trained professionals who alternated weekly. 
The ventilatory anaerobic threshold is considered the main measure of aerobic fitness(33), as other studies 
in SLE(31,32) and fibromyalgia (33–35) fail to achieve maximum effort when submitted to maximal 
exercise test protocol in the treadmill. Lemos et al has demonstrated, by using mathematical models, that 
for exercise prescription in the anaerobic threshold intensity for sedentary women with fibromyalgia, the 
percentage must be 75.5-80.9% HRmax. Once our preliminary results showed that pSS also do not achieve 
a maximum effort, the intensity of the exercise was based on the heart rate (HR) at 80% of the maximum 
heart rate (HRmax) reached in the treadmill test(34).  
The HR of the patients was registered with a pulse watch (Polar® A1, Kempele, Finland) and ratings of 
the general perceived exertion (RPE) rated on the Borg RPE 0-10 scale [21]  at the beginning, middle and 
end of the effective walking time. Each training session was preceded by a warm-up period, when 
patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of 
effective walking when they were instructed to maintain their paces to achieve the target HR, and ending 
with a cooling down period for 5 minutes (similar to warm up period). Increasing duration of exercise 
was made as follow: 20 minutes in the first 2 weeks, adding 5 minutes per week until eighth week, 
completing 50 minutes, which remains until the end of the program.  
Physical fitness outcomes 
All patients performed a maximal exercise test on the treadmill (Super ATL, Inbramed, Porto Alegre, 
Brazil), directed by the software Ergo PC (Micromed, Brasília, Brazil) and supervised by a cardiologist, 
who performed a screening process for cardiac risk. The protocol begins with a warm-up period of 3 
minutes at 3 km/h and increases 1 km/h each minute until 7 km/h, from this moment 2,5% inclination is 
added until 15% in the 13º minute(33,36). The electrocardiogram (Micromed, Brasília, Brazil) and blood 
pressure were closely monitored throughout the exercise test which was interrupted when appearance of 
abnormal signs or at patient’s request in case of any discomfort.   
The maximum oxygen uptake (VO2max, ml/kg/min) was calculated by the walking metabolic equation of 
the American College of Sports Medicine (ACSM): VO2 = 0.1(speed) + 1.8 (speed) (fractional grade) + 
3.5(37,38). 
The highest value obtained in the last load was taken as peak heart rate (HRpeak). The distance reached 
during the test was also recorded. 
 
Clinical outcomes 
The disease activity was measured by the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) 
(15,39), fatigue by the Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-
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Fatigue) (40),  perception of pSS’s symptoms by the EULAR Sjögren’s Syndrome Patient Reported Index 
(ESSPRI) (27,41), depression by the Beck Depression Inventory (BDI)(42) and quality of life by the 
Medical Outcomes Study 36 (SF-36) (43).  
 
Patient global assessment of response to therapy (PGART) 
At the final assessment the patients responded on the PGART using a 5-point scale (1=much better, 2 
=better, 3=slightly better, 4=no change, and 5=worse). 
 
Statistical analysis 
The main hypothesis was that aerobic exercise improves VO2max (ml/kg/min) and clinical outcomes, such 
as fatigue, pain, depression and quality of life without exacerbating disease activity. An intent-to-treat 
analysis was performed and a level of significance of p<0.05 was accepted for the trial. To compare the 
effects of the two groups, the independent and dependent variables and the RPE over the time were 
analysed using a repeated-measures analysis of variance (ANOVA). Independent sample t-tests or Mann–
Whitney U tests were used in the between groups comparison when interaction time (baseline, 8 and 16 
weeks) x group (TG and CG) was statistically significant and in the between groups comparison of the 
mean change after 16 weeks. Chi-square test and binomial test with Bonferroni correction were used to 
determine differences in rates of improvement between the groups. Pearson’s and Spearman’s correlation 
coefficients were used to investigate the association between the improvement of VO2max (ml/kg/min) and 
clinical outcomes. The comparison between the HR at the final time of the third session in each week of 
the training and the target HR was analysed by paired t-test and Pearson’s correlation coefficient. The 
last-observation-carried-forward method was performed for missing data. A statistician blinded to the 
groups performed the analysis using version 19.0 of the SPSS software system. 
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RESULTS  
A flow diagram showing the movement of participants through the study is shown in Fig. 1.  Forty five 
eligible patients were randomized to groups (TG: 23; CG: 22). Four patients in TG and 2 in CG 
discontinued the intervention. One patient in the TG refused to undergo evaluations at week 8 and week 
16 after reporting chest pain in the 1st week, and 1 patient in the CG refused to undergo evaluation at 
week 16 due to personal problems. Three patients in the TG could not perform the exercise test at week 
16 following adverse events unrelated to the exercise program: the first reported an acute low back pain in 
the 6th week, the second suffered a foot fracture due to a fall from the stairs in the 7th week, and the third a 
trochanteric bursitis in the 10th week. One patient of the CG could not perform the exercise test at week 
16 due to hip arthralgia.  
There were no statistically significant differences between study groups at baseline (Table 1 and Table 2) 
with one exception: the number of patients using non-steroidal anti-inflammatory drugs was higher in the 
TG than in the CG (52.2% vs. 22.7%, p=0.042) (supplementary table S1). None of them were smokers. 
Patients discontinuing the intervention scored slightly lower on the mental component summary (MCS) 
of the SF-36 (p=0.041) compared to those completing the study (Table 1). 
The compliance rate for the exercise program sessions averaged 72.4% (21 - 92%). In case of pain or 
fatigue, training intensity was maintained but the duration of the session reduced. Three patients in the 
TG group reported fatigue, 5 widespread pain, 2 low back pain, 4 knee arthralgia, 2 hip/ankle arthralgia, 1 
shoulder arthralgia and 2 hand/wrist arthralgia during the exercise program. However, all of them were 
transitory and did not affect the continuity in the exercise program and patients did not attribute these 
symptoms to exercise. The complaints of the patients in CG were not registered weekly, but 1 reported 
worsening in fatigue, 2 widespread pain pain, 1 knee arthralgia, 1 hip arthralgia and 2 hand/wrist 
arthralgia at week 16. 
Three patients of the TG modified the pharmacological treatment during the trial: the first exchanged the 
hydroxychloroquine for methotrexate (pruritus in skin), the second started the use of methotrexate and 
corticosteroids (vasculitis in legs), and the third started the use of azathioprine (worsening of xerostomia 
and xerophthalmia). Methotrexate was introduced for one patient of the CG (persistent arthritis in hands). 
 
Physical fitness 
At baseline only 52% of the patients in the TG and 50% in the CG reached the maximal effort in the 
treadmill test. The VO2max (ml/kg/min) increased in both groups (p=0.025) and HRpeak remained the same.  
However the distance covered on the test increased only in TG (p=0.020). The mean change in VO2max 
and distance after 16 weeks was higher in the TG than in the CG (p=0.016 and p=0.043, respectively) 
(Table 3 and Fig. 2).  
There was correlation between the improvement of VO2max and improvement of the FACIT-fatigue 
(r=0.418, p=0.047), SF-36 domains physical functioning (r=0.557, p=0.006) and general health (r=0.525, 
tp=0.010) and SF-36 physical component summary (PCS) (r=0.478, p=0.021) only in TG. 
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The mean difference of the training HR and the target HR was higher than 5 beats per minute (bpm) only 
in the 6th, 13th and 16th week of the exercise program. There was a high correlation between the mean 
training HR and mean target HR (r=0.943, p=0.006, Pearson). The mean of the general RPE was 3.18 ± 
0.33 (2.6 - 3.9) with no difference over the exercise program (p=0.818). 
Eleven patients (47.8%) in the TG and 5 (22.7%) in the CG had an improvement over 15% in VO2max at 
week 16.  While this difference was not statistically significant (p=0.079), those patients in the TG with 
15% VO2max gain showed significant improvements in FACIT-fatigue (p=0.047), ESSPRI fatigue (p= 
0.044) and BDI (p=0.037) compared to those with less than 15% gain in VO2max. In TG, the number of 
patients presenting with widespread pain at baseline was higher in the subgroup of patients with no gain 
in VO2max compared to those with improved VO2max gain (10 vs 4, p= 0.021) (Table 4).  
 
Clinical data 
Fatigue measured by FACIT-fatigue improved only in TG (p=0.017). There was no difference in the 
ESSPRI domains and total score in both groups. Depression measured by BDI improved in TG and CG 
over time (p=0.001), from baseline to week 8 (19±10 to 15±9 and 20±12 to 18±12, p=0.005, respectively) 
and from baseline to week 16 (19±10 to 15±10 and 20±12 to 16±12, p=0.001, respectively). Both groups 
showed improved MCS of the SF-36 (p=0.009). There were no differences in the PCS of the SF-36, 
despite the tendency of improvement in the TG (Table 3). There was a difference between groups in mean 
changes after 16 weeks only in FACIT-fatigue (p=0.030) (Table 3). 
The improvement of fatigue (FACIT-fatigue) in the TG was correlated with the improvement of the 
VO2max (ml/kg/min) (r=0.418, p=0.047), ESSPRI-fatigue (r=-0.677, p<0.001), ESSPRI pain (r=-0,429, 
p=0,041), ESSPRI-total (r=-0.630, p=0.001), BDI (r=-0.474, p=0.022), SF-36 domains physical 
functioning (r=0.682, p=0.001), role-physical (r=0.552, p=0.006), general health (r=0.423, p=0.044), 
social functioning (r=0.425, p=0.043) and mental health (r=0.586, p=0.003), SF-36 PCS (r=0,522, 
p=0,011) and SF-36 MCS (r=0.456, p=0.0290). While in the CG there was association between the 
improvement of fatigue (FACIT-fatigue) only with ESSPRI-fatigue (r=-0.694, p<0.001), ESSPRI-total 
(r=0.496, p=0,019) and BDI (r=-0.477, p=0.025). 
 
Immunological data and ESSDAI 
There was no difference in ESSDAI, erythrocyte sedimentation rate (ESR), IgG, IgA, IgM and C3 over 
time. The C reactive protein (CRP) (p=0.005), creatine kinase (CK) (p=0.018) and C4 (p<0.001) levels 
increased in both groups. There was no difference between groups in all these data (supplementary Table 
S2). 
At baseline, 65.2% of the patients in the TG were classified as having low disease activity by ESSDAI 
classification [25], 26.1% moderate and 8.7% high; and in the CG the percentages were 63.6%, 31.8% 
and 4.5%, respectively. There was no difference within-groups after 16 weeks (p=0.538) and between 
groups (p=0.809). 
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PGART 
The categories of the PGART were statistically different at the final assessment between groups 
(p=0.049). From the TG, 95.4% of the patients rated themselves as clinically improved versus 62% of the 
patients in the CG. 
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DISCUSSION 
This is the first randomized controlled trial with intention-to-treat analysis to demonstrate that a 16-week 
supervised walking program improves the cardiorespiratory fitness, exercise tolerance, fatigue and patient 
perception of improvement without exacerbating disease activity in women with pSS.  
The TG improved the cardiorespiratory fitness (VO2max) more than the CG, demonstrating that the 
program was effective in enhancing cardiorespiratory fitness.  This is consistent with a study of 
supervised aerobic exercise in patients with SLE(8). In a study of Nordic walking exercise performed 
three times a week for 12 weeks in pSS(13), VO2max (l/min) improved significantly, but not the VO2max 
(ml/kg/min). However these patients were supervised just once a week. The improvement of the 
cardiorespiratory fitness was not observed in the other 4 exercise studies in SLE(7,9–11), an autoimmune 
disease with several clinical similarities to pSS(44), probably because the exercises were not supervised 
during the whole program. It may be that such supervision is important to the cardiorespiratory fitness 
improvement. Unexpectedly, the there was a small but statistically significant improvement (151.1±18.6 
vs. 152.3±17.8, p=0.023) in [what] in the CG though this may be attributable to treadmill exercise 
learning. 
The intensity of our exercise program at 80% of the HRpeak reached in the treadmill test and the gradually 
increasing duration of exercise showed to be appropriated to the pSS patients since there was no 
difference between the training HR and the target HR in most of the weeks and the perceived exertion 
(BORG scale) remained moderate over the entire program.  This might have contributed to provide a 
good adherence to the exercise program (72%). The intensity of the exercise prescribed in previous SLE 
and pSS studies(7,9–11,13) increased progressively over the training from 60% or 70% to the maximum 
of 80% of the HRmax and most of them improved fatigue and exercise tolerance(9–11,13).  While largely 
safe (9–11) these studies did not improve cardiorespiratory fitness as mentioned before. In addition to 
supervision, the only study in SLE that improved cardiorespiratory fitness used the HR training 
corresponding to the ventilatory anaerobic threshold during the whole program(8). The same method of 
prescription was used for patients with fibromyalgia also with an improvement in cardiorespiratory 
fitness(45,46). Lemos et al have demonstrated that the percentage of the exercise prescription in the 
anaerobic threshold intensity for sedentary women with fibromyalgia syndrome must be from 75% to 
80% of the HRmax reached in the treadmill test(34). These percentages are higher than the ACSM 
recommendation (55-64% HRmax) to sedentary [] (47), which may be owing to the fact that patients with 
fibromyalgia do not take maximum effort and HRmax is underestimated. While there is no comparable 
study in pSS, our results showed that pSS patients also do not take maximum effort.  This suggests that 
the same method of exercise intensity prescription might extrapolate to other diseases sharing reduced 
cardiorespiratory fitness and concomitant symptoms, such as fatigue, musculoskeletal pain and autonomic 
dysfunction. 
The change in exercise distance of the TG is likely to be due to improved exercise tolerance and 
cardiorespiratory fitness and is important because improved exercise capacity may reflect improvements 
in physical disability. Although this was not supported by any significant changes in self-perceived 
measures of physical function, probably due to the small sample size to detect differences in SF-36 
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between groups, a significant moderate association was found between the improvement of 
cardiorespiratory fitness and the improvement of fatigue and all physical domains of the SF-36.  In fact, 
fatigue measured by FACIT-fatigue in TG improved more than in CG, and the mean difference of the 
ESSPRI fatigue domain was of -1 in the TG.  This is considered clinically significant(48), but not 
statistically significant, consistent with other reports that it is insensitive to change(49). These findings 
suggest an important role of the physical fitness in the pathogenesis of the fatigue in pSS. 
Surprisingly, both groups showed improved depression score and MCS of the SF-36.  Patients of the CG 
had 5 more meetings with health-care professionals due to the study than the usual of 2 meetings/year. 
This additional attention could have been a factor in increasing mood, motivation, and effort.  In contrast 
with Strömbeck, Theander and Jacobsson study(13), there was no difference in depression between TG 
and CG groups.  However, our correlation analysis shows that improvements in fatigue are associated 
with improvements in depression scores. Furthermore, the complementary analysis in TG showed that an 
increase above 15% in VO2max improves both fatigue and depression. Exercise is known to increase 
tryptophan transport into the brain and serotonin production, which is one of the crucial mechanisms of an 
antidepressant action(50).  
It’s possible that the three patients of the TG who modified the pharmacological treatment during the trial 
had some improvement in their clinical data and physical fitness, but one patient of the CG also started 
the use of a new drug, extending the effect for both groups. The patient of the TG who started the use of 
methotrexate and corticosteroids due to the worsening of vasculitis in legs was evaluated by the 
rheumatologist, who recommended the continuity of the exercise program to conclude that it was not a 
worsening of the disease activity. 
In general, as with SLE patients(7,9–11), there was no flare in disease activity and no serious adverse 
events with exercise, showing that patients with pSS can undergo physical training without damage. 
Although both groups had an incomprehensible increased of CRP, CK and C4 levels after 16 weeks, 
ESSDAI had a slight non-significant reduction, which means that patients remained stable regarding on 
disease activity. Two patients of the CG related worsening at the final assessment and only one in the TG, 
but she is the one who discontinued the intervention due to the low-back pain. This patient had only 56% 
compliance, severe depression by BDI, reported worsening of widespread pain, and serious personal 
problems. On her magnetic resonance imaging scan there was no evidence of injury, implying a strong 
emotional influence on her pain symptoms. As we did not systematically registered emergence of new or 
transitory symptoms in CG, such as pain and fatigue, it seems that patients of the TG had more 
complaints, but most of them did not attribute these symptoms to the exercise program, with the 
exception of one patient suffering from trochanteric bursitis with prior history in the past.  
Given reduced physical capacity and function(24,51) and lower levels of physical activity in patients with 
pSS when compared to healthy people(22,23), aerobic exercise becomes an important intervention to 
improve cardiorespiratory fitness, decrease fatigue and probably the risks of developing secondary 
chronic disease.  
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The limitations of the study are the indirect measurement of the VO2max, non-validation of the ACMS 
metabolic equation to this population, lack of weekly monitoring of the new symptoms in the CG and 
lack of a follow-up to date investigating the long-term effects of the exercise program.  
In conclusion, this supervised walking program was demonstrated to be feasible and safe with 
improvement of the cardiorespiratory fitness, exercise tolerance, fatigue and perception of clinical 
improvement in women with pSS patients. 
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